title: Atherothrombogenic risk modulation by n-3 fatty acids was not associated with changes in homocysteine in subjects with combined hyperlipidaemia.
abstract: Favourable effects of n-3 fatty acids on the atherogenic risk profile were recently demonstrated in subjects with combined (type IIb) hyperlipidaemia, not responding to a therapeutic diet. Re-examination of a previous patient material was performed to assess the influence of n-3 fatty acids on homocysteine and several coagulation factors. Subjects were randomly allocated to receive either a concentrated compound of 85% eicosapentaenoic acid (EPA)/docosahexaenoic acid (DHA) (n = 28), or corn oil (n = 29), in a daily dose of 4g for 12 weeks. The intervention was double-blind. Homocysteine remained unchanged in both groups after 12-week treatment. N-3 fatty acids supplementation did not affect the levels of fibrinogen, coagulation factor VII or tissue factor pathway inhibitor (TFPI), while plasminogen activator inhibitor (PAI) increased significantly (Student's t-test; p <0.05). Total blood platelets were significantly reduced in subjects receiving n-3 fatty acids (Student's t-test; p <0.05), whereas bleeding times increased non-significantly.
authors.affiliation: Department of Medicine, Central Hospital in Rogaland, Stavanger, Norway.
authors.forename: H
authors.initials: H
authors.lastname: Grundt
authors.forename: D W
authors.initials: DW
authors.lastname: Nilsen
authors.forename: O
authors.initials: O
authors.lastname: Hetland
authors.forename: M A
authors.initials: MA
authors.lastname: Mansoor
authors.forename: T
authors.initials: T
authors.lastname: Aarsland
authors.forename: L
authors.initials: L
authors.lastname: Woie
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001161:Arteriosclerosis / Q000453:epidemiology* / Q000517:prevention & control*; D001760:Bleeding Time; D015992:Body Mass Index; D004311:Double-Blind Method; D005227:Fatty Acids / Q000097:blood; D015525:Fatty Acids, Omega-3 / Q000627:therapeutic use*; D005260:Female; D006710:Homocysteine / Q000097:blood*; D006801:Humans; D020138:Hyperhomocysteinemia / Q000517:prevention & control; D006949:Hyperlipidemias / Q000097:blood; D008297:Male; D008875:Middle Aged; D010349:Patient Compliance; D010743:Phospholipids / Q000097:blood; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood; D010976:Platelet Count / Q000187:drug effects; D012307:Risk Factors; D013927:Thrombosis / Q000453:epidemiology* / Q000517:prevention & control*; D014280:Triglycerides / Q000097:blood
chemical_list: D005227:Fatty Acids; D015525:Fatty Acids, Omega-3; D010743:Phospholipids; D017395:Plasminogen Activator Inhibitor 1; D014280:Triglycerides; D006710:Homocysteine